Myeloproliferative neoplasms trials in Italy

In Italy 42 Also abroad 210

42 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Where
Alexandria, Bologna, Florence, Varese
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06351631 · EU 2023-506996-89-00
Phase 3Taking people
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Where
Bologna, Castelfranco Veneto, Florence, Meldola, Milan, Monza, Naples, Novara, Orbassano, Padova, Palermo, Rome, Turin, Udine, Verona
Age
18 years and over
People
460 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Genoa, Meldola, Milan, Pisa, Rome, Turin
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Where
Ancona, Bologna, Catania, Ferrara, Florence, Meldola, Milan, Rome, Turin, Udine
Age
18 years and over
People
324 worldwide
Run by
Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00
Phase 3Taking people
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Where
Bari, Bergamo, Bologna, Catania, Florence, Genova, Meldola, Milan, Novara, Pavia, Rome, Torino, Udine, Verona
Age
18 years and over
People
426 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
Bologna, Milan
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 2Taking people
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Where
Bologna, Catania, Florence, Meldola, Milan, Rome
Age
18 years and over
People
68 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00
Phase 1Taking people
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Where
Bologna, Milan, Roma, Udine
Age
18 years and over
People
218 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00
Phase 3Taking people
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Where
Alexandria, Ancona, Bergamo, Bologna, Cesena, Florence, Forli', Genoa, Meldola, Milan, Monza, Naples, Novara, Pavia, Pesaro, Rome, Turin, Udine, Verona, Vicenza
Age
18 years and over
People
250 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00
Phase 1Taking people
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Where
Florence, Ravenna, Rome
Age
18 years and over
People
100 worldwide
Run by
Prelude Therapeutics Incorporated
See details and how to joinNCT07469891 · EU 2026-525484-40-00
Phase 1Taking people
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Where
Bologna, Milan
Age
18 years and over
People
256 worldwide
Run by
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00
No phaseTaking people
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Where
Milan
Age
16 years and over
People
1,190
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07863466
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Alexandria, Aviano, Bologna, Brescia, Catania, Meldola, Milan, Monza, Novara, Turin, Varese
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00
Phase 2Taking people
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Where
Bologna, Genoa, Meldola, Milan, Novara, Pavia, Rome, Turin
Age
18 years and over
People
38 worldwide
Run by
Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 · EU 2024-511309-47-00
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Bari
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Bologna, Florence, Salerno, Verona
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Where
Alexandria, Ancona, Bologna, Brescia, Catania, Florence, Meldola, Milan, Novara, Orbassano, Palermo, Pavia, Pesaro, Ravenna, Reggio Emilia, Rome, Turin, Varese
Age
18 years and over
People
126 worldwide
Run by
Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 · EU 2023-504724-25-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Bologna, Meldola, Milan
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 1/2Taking people
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)
Where
Bologna, Florence, Meldola, Naples, Reggio Calabria, Rome, Turin, Udine
Age
18 years and over
People
27 worldwide
Run by
iOnctura SA
See details and how to join2024-515252-20-00 · EU 2024-515252-20-00
Phase 1Taking people
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Where
Bergamo, Florence, Milan, Verona
Age
18 years and over
People
120 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07008118
No phaseTaking people
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Where
Alessandria, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cuneo, Ferrara, Florence, Messina, Mestre, Milan, Monza, Naples, Novara, Padova, Palermo, Pavia, Pisa, Roma, San Giovanni Rotondo, Torino, Trieste, Udine, Varese, Verona, Vicenza
Age
18 years to 100 years
People
429 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06506084
No phaseTaking people
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Where
Alessandria, Bergamo, Bologna, Catania, Florence, Milan, Monza, Naples, Novara, Pavia, Roma, Torino, Tricase, Verona, Vicenza
Age
18 years to 100 years
People
617 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06533813
No phaseTaking people
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Where
Alessandria, Bergamo, Bologna, Brescia, Florence, Milan, Monza, Naples, Novara, Pavia, Pescara, Roma, Verona, Vicenza
Age
18 years to 100 years
People
678 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT07203768
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Allessandria, Bologna, Brindisi, Cagliari, Ferrara, Florence, Genoa, Lecce, Milan, Modena, Naples, Orbassano, Pavia, Reggio Calabria, Roma, Rozzano, Varese, Verona
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 1/2Taking people
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Where
Bologna, Florence, Meldola, Rozzano, Udine
Age
18 years and over
People
26 worldwide
Run by
iOnctura
See details and how to joinNCT06887803